Voyager Therapeutics, Inc. (VYGR)

CIK 0001640266 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-06) · 99.1
Q1-2026 8-K (2026-05-07) · 99.1
Latest FY-2025 8-K (2026-03-09) · 99.1
Q3-2025 8-K (2025-11-10) · 99.1
Q2-2025 8-K (2025-08-06) · 99.1
Q1-2025 8-K (2025-05-06) · 99.1
FY-2024 8-K (2025-03-11) · 99.1
Q3-2024 8-K (2024-11-12) · 99.1
Q2-2024 8-K (2024-08-06) · 99.1
Q1-2024 8-K (2024-05-13) · 99.1
FY-2023 8-K (2024-02-28)  |  8-K (2024-01-02)
Q3-2023 8-K (2023-11-06) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Condensed Consolidated Statements of Operations and Comprehensive Loss
—
Consolidated Statements of Operations and Comprehensive (loss) Income
Consolidated Statements of Operations and Comprehensive Income (loss)
—
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Cash Flows
Notes
401(k) Savings Plan
—
Accrued Expenses
Cash Equivalents and Available-for-sale Marketable Securities
—
Cash, Cash Equivalents, Restricted Cash, and Available-for-sale Marketable Securities
—
Commitments, Contingencies and Other Liabilities
Commitments, Contingencies, and Other Liabilities
—
Common Stock
—
Cybersecurity Risk Management and Strategy Disclosure
—
Fair Value Measurements
Income Taxes
—
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Lease Obligation
Nature of Business
Net (loss) Income Per Share
—
Net Loss Per Share
—
Other Liabilities
—
Pay Vs Performance Disclosure
Prepaid Expenses and Other Current Assets
—
Property and Equipment, Net
—
Related Party Transactions
Related-party Transactions
Segment Information
Significant Agreements
Stock-based Compensation
Subsequent Events
Summary of Significant Accounting Policies and Basis of Presentation
Underwritten Public Offering